Valuation : Standard BioTools Inc.

Market Cap 252M 217M 204M 186M 350M 24.08B 351M 2.42B 942M 12.16B 946M 926M 40.31B P/E 2026 *
-6.42x
P/E 2027 * -4.01x
Enterprise Value 252M 217M 204M 186M 350M 24.08B 351M 2.42B 942M 12.16B 946M 926M 40.31B EV / Sales 2026 *
3.05x
EV / Sales 2027 * 3.07x
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Standard BioTools Inc.

1 day-1.70%
1 week-4.05%
Current month-26.05%
1 month-28.46%
3 months-44.18%
6 months-41.65%
Current year-49.85%
1 week 0.64
Extreme 0.6357
0.67
1 month 0.63
Extreme 0.6251
0.91
Current year 0.63
Extreme 0.6251
1.67
1 year 0.63
Extreme 0.6251
1.72
3 years 0.63
Extreme 0.6251
3.16
5 years 0.63
Extreme 0.6251
7.28
10 years 0.63
Extreme 0.6251
14.9
Manager TitleAgeSince
Director of Finance/CFO 55 2024-08-31
Chief Executive Officer 63 2021-09-30
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 72 2022-03-31
Director/Board Member 53 2022-04-03
Director/Board Member 63 2021-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/20/26 Tax

Founder

-28,195 0.0072%
8/20/26 Tax

Executive/Senior Manager

-25,729 0.0066%
8/20/26 Tax

Chief Executive Officer

-97,627 0.0249%
Change 5-day change 1-year change 3-year change Capi.($)
-1.70%-4.05%-49.06%-78.31% 252M
-1.35%-1.13%+26.27%+11.30% 230B
+0.18%-1.27%+4.98%-18.21% 152B
+1.51%-1.64%-21.28%+16.96% 132B
+0.36%-7.01%-55.60%-13.69% 67.88B
+0.29%+0.47%+10.90%+15.92% 52B
-0.34%-2.57%-17.51%-14.92% 51.05B
-2.44%-3.25%+22.43%+25.40% 43.38B
-1.56%+0.97%+37.41%+44.40% 40.74B
+1.94%+3.81%-12.45%+46.38% 34.67B
Average -0.42%-1.48%-5.39%+3.52% 80.35B
Weighted average by Cap. -0.12%-1.46%+2.43%+7.10%

Financials

2026 *2027 *
Net sales 82.5M 71.09M 66.65M 60.85M 115M 7.88B 115M 791M 309M 3.98B 310M 303M 13.2B 82.1M 70.75M 66.33M 60.55M 114M 7.85B 114M 787M 307M 3.96B 308M 302M 13.13B
Net income -38.8M -33.43M -31.35M -28.62M -53.91M -3.71B -54.08M -372M -145M -1.87B -146M -143M -6.21B -62.9M -54.2M -50.82M -46.39M -87.39M -6.01B -87.67M -603M -235M -3.03B -236M -231M -10.06B
Net Debt - -
Logo Standard BioTools Inc.
Standard BioTools Inc. has a portfolio of technologies that help biomedical researchers develop medicines faster. The Company develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The Company's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.
Employees
387
Date Price Change Volume
26-08-31 US$0.6472 +0.82% 250,373
26-08-28 US$0.6419 -1.70% 1,260,474
26-08-27 US$0.6530 +0.18% 1,487,311
26-08-26 US$0.6518 +0.28% 1,337,254
26-08-25 US$0.6500 0.00% 1,306,640
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.6419USD
Average target price
1.350USD
Spread / Average Target
+110.31%

Quarterly revenue - Rate of surprise